Federal Circuit Vacates PTAB’s Inter Partes Review Decision That Concluded a Petitioner Failed to Prove Claims Would Have Been Obvious

Nov 18, 2015

Reading Time : 1 min

In two separate IPR petitions Ariosa alleged that all claims of Verinata’s patent would have been obvious in 2010 based on three prior-art references. The PTAB instituted review but ultimately found that Ariosa failed to carry its burden to prove invalidity. Among other things, the Board criticized a second declaration that Ariosa submitted, which relied on a brochure that described nucleotide sequencing using a commercially available instrument. The Board stated:

This testimony, in effect, replaces [teachings of two of the cited references] with [teachings of the brochure], but neither Petitioner nor [the declarant] explains why [the brochure] could not have been presented as part of the asserted ground of unpatentability in the first instance with the Petition. Therefore we accord this aspect of [the declarant’s] testimony no weight. (emphasis added)

The Federal Circuit noted that Ariosa’s Petitions and opening declarations cited the brochure to explain the knowledge of skilled artisans at the time. The Court found the PTAB’s decision unclear as to whether the PTAB had refused to consider the brochure for any reason at all, including for what it showed about the background knowledge of a skilled artisan, which would have been legal error. Thus, the Court vacated and remanded for clarification, specifically noting that the PTAB need not take new evidence or even accept new briefing; it was free to control the proceeding on remand as it saw fit to address the Court’s concern.

Ariosa had also challenged the PTAB’s refusal to consider portions of one of the prior-art references that the PTAB found Ariosa had cited only in its Reply submissions. The Federal Circuit found no error in the PTAB’s “rejection of Ariosa’s reliance, it its Reply submissions, on previously unidentified portions of a prior-art reference to make a meaningfully distinct contention.”

Ariosa Diagnostics v. Verinata Health, Inc., Nos. 15-1215; -1226 (Fed. Cir. Nov. 16, 2015)

Share This Insight

Previous Entries

IP Newsflash

December 9, 2025

The Federal Circuit recently denied a petition for a writ of mandamus that challenged the PTO Director’s reliance on “settled expectations” to discretionarily deny two inter partes review (IPR) petitions. In so doing, the court explained that, while it was not deciding whether the Director’s use of “settled expectations” was correct, the petitioner’s arguments about what factors the Director may consider when deciding whether to institute an IPR or post-grant review (PGR) are not generally reviewable and did not provide sufficient basis for mandamus review here.

...

Read More

IP Newsflash

December 5, 2025

District courts are split on whether a complaint can provide the required knowledge for post-suit indirect and willful infringement in that same lawsuit. Chief Judge Connolly in the District of Delaware recently confirmed that, consistent with his prior opinions, the complaint cannot serve as the basis for knowledge for either a claim of post-suit indirect infringement or a demand for willfulness-based enhanced damages in that lawsuit.

...

Read More

IP Newsflash

December 3, 2025

The Federal Circuit recently held that a patentee acted as its own lexicographer to define a claim term even though it did not explicitly define the term. Rather, because the patentee consistently and clearly used two terms interchangeably to describe the same structural feature and did so in all of the embodiments in which the feature appeared, the patentee impliedly gave the term its own, unique definition.

...

Read More

IP Newsflash

December 2, 2025

The Federal Circuit recently held an asserted patent was not entitled to its priority date because the priority application lacked written description support for the asserted claims. In so doing, the court explained that broad disclosures that do not provide reasonably specific support for narrower claims do not meet the written description requirement. The court also considered whether the inventor’s testimony showed they possessed the full scope of the claimed genus at the priority date or whether it was more likely the inventors first became aware of the claimed embodiments from public disclosures of the accused product.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.